| First Author | Hackett CS | Year | 2014 |
| Journal | Cell Rep | Volume | 9 |
| Issue | 3 | Pages | 1034-46 |
| PubMed ID | 25437558 | Mgi Jnum | J:217469 |
| Mgi Id | MGI:5614146 | Doi | 10.1016/j.celrep.2014.09.046 |
| Citation | Hackett CS, et al. (2014) Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma. Cell Rep 9(3):1034-46 |
| abstractText | The development of targeted therapeutics for neuroblastoma, the third most common tumor in children, has been limited by a poor understanding of growth signaling mechanisms unique to the peripheral nerve precursors from which tumors arise. In this study, we combined genetics with gene-expression analysis in the peripheral sympathetic nervous system to implicate arginase 1 and GABA signaling in tumor formation in vivo. In human neuroblastoma cells, either blockade of ARG1 or benzodiazepine-mediated activation of GABA-A receptors induced apoptosis and inhibited mitogenic signaling through AKT and MAPK. These results suggest that ARG1 and GABA influence both neural development and neuroblastoma and that benzodiazepines in clinical use may have potential applications for neuroblastoma therapy. |
